ATOS

Atossa Therapeutics, Inc. Common Stock

2.23

USD

-0.14

-5.91%

Oct 29, 15:59 UTC -4

Closed

Pre-Market

2.23

0.00

-0.22%

Atossa Therapeutics, Inc. Common Stock (ATOS) Earnings

ATOS Earnings Reports

Positive Surprise Ratio

ATOS beat 22 of 34 last estimates.

65%

Next Report

Date of Next Report

Nov 10, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.90

Implied change from Q2 26 (Revenue/ EPS)

-5.26%

Implied change from Q3 25 (Revenue/ EPS)

-14.29%

Atossa Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 07, 2026, ATOS reported earnings of -0.95 USD per share (EPS) for Q2 26, beating the estimate of -1.04 USD, resulting in a 9.13% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.48% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.90 USD, with revenue projected to reach -- USD, implying an decrease of -5.26% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Gilead Sciences Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.24

Actual

$2.54

Surprise

+13.66%

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Incyte Genomics Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$3.92

Actual

-$3.60

Surprise

+8.33%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

Ligand Pharmaceuticals Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.42

Actual

$2.67

Surprise

+9.91%

Fortrea Holdings Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.22

Actual

$0.28

Surprise

+26.53%

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

FAQ

What were Atossa Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Atossa Therapeutics, Inc. Common Stock reported EPS of -$0.95, beating estimates by 9.13%, and revenue of $0.00, 0% as expectations.

How did the market react to Atossa Therapeutics, Inc. Common Stock's Q2 2026 earnings?

The stock price moved down -2.48%, changed from $2.42 before the earnings release to $2.36 the day after.

When is Atossa Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Nov 10, 2026.

What are the forecasts for Atossa Therapeutics, Inc. Common Stock's next earnings report?

Based on 5 analysts, Atossa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.90 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.